Avastin-Related Eye Infections Could Bring FDA Pressure On Compounding Pharmacies
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA alert about a cluster of Streptococcus endophthalmitis infections in Florida suggests concerns about aseptic conditions in pharmacies that repackage Avastin for off-label intravitreal use.
You may also be interested in...
Regeneron Touts Potential Of Growing Eylea Franchise After Robust Q4
Speaking at the J.P. Morgan meeting in January, Regeneron CEO Leonard Schleifer says the company is exploring many opportunities to build the franchise around its successful wet AMD drug Eylea. In the fourth quarter, the drug racked up $400 million in U.S. sales, beating expectations.
NICE’s Off-Label Drug Guide Doesn’t Imply Support – Even For Pfizer
With safety in mind, NICE is to publish product summaries on the off-label use of specific medicines, but stresses that this is not meant to encourage the practice.
FDA’s Compounding Oversight: What Price Safety?
As meningitis outbreak widens, FDA and members of Congress are calling for clarification of what jurisdiction the agency has over pharmacies, but agency officials are stopping short of asking for clear new authorities.